Qiming leads series B for cancer play WindMIL

WindMIL Therapeutics Inc. (Baltimore, Md.) raised $32.5 million on June 18 in an untranched series B round led by Qiming Venture Partners. Fellow new investors Medivate Partners, Camden Partners Nexus and the Kinneret Group participated alongside existing investors Domain Associates and FoxKiser.

WindMIL is developing genetically modified and unmodified marrow infiltrating lymphocytes (MILs), a cell immunotherapy based on bone marrow-derived lymphocytes. The company is testing unmodified MILs in a Phase II trial to treat multiple myeloma. President and CEO Brian Halak, who is also a partner at Domain, told BioCentury that WindMIL plans to start two clinical trials of unmodified MILs in the near future to treat solid cancers...